Aurobindo Pharma Q2FY27 Revenue Surges 24% YoY to ₹10,263 Cr; Net Profit Rises 33%
Aurobindo Pharma reported Q2FY27 consolidated revenue of ₹10,263 crore, up 24% YoY. Net profit rose 32.5% to ₹1,124 crore. US revenue grew 25% to ₹4,555 crore and Europe revenue increased 27% to ₹3,161 crore. The company declared an interim dividend of ₹7 per share and received 12 USFDA approvals.
The announcement details robust financial results with significant growth in revenue and profit, key market expansion, and positive future outlook, which are material events for investors and the company's valuation.
The company reported strong year-on-year growth in revenue and net profit, along with significant increases in key geographical markets and a declared interim dividend, indicating a positive financial performance.
Aurobindo Pharma Limited announced its consolidated financial results for the second quarter and half year ended September 30, 2026.
The company reported its highest ever quarterly Revenue from Operations of ₹10,263 crore, marking a 24% year-on-year increase. This growth was driven by strong performance across its key businesses.
US revenue saw a significant jump of 25% YoY to ₹4,555 crore (USD 477 million), while Europe revenue increased by 27% YoY to ₹3,161 crore (EUR 288 million). Growth Markets revenue grew by 16% YoY to ₹1,026 crore (USD 107 million), and ARV revenue stood at ₹359 crore (USD 38 million).
Net Profit for the quarter was ₹1,124 crore, a 32.5% increase YoY. EBITDA (Before Forex and Other Income) was ₹2,156 crore, up 28.5% YoY, with an EBITDA Margin of 21.0%.
The company received final approval for 12 products from the USFDA. R&D expenditure for the quarter was ₹376 crore. Aurobindo Pharma generated strong free cash flows of USD 146 million during the quarter and maintained a net cash position of USD 189 million as of September 30, 2026.
Basic and Diluted EPS stood at ₹19.57 per share. The company declared an interim dividend of ₹7.0 per share.
Commenting on the performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director, stated, “We are pleased to deliver a strong performance in Q2, reflecting the strength of our business fundamentals, sustained execution and the resilience of our diversified product portfolio.”
The company will host an earnings call at 8:30 AM IST on November 5, 2026, to discuss the performance.
What to do with a filing like this
Aurobindo Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aurobindo Pharma Limited. Read the original for the full detail.